A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single‐arm neoadjuvant trial with letrozole and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Takayuki, Masuda, Norikazu, Kamigaki, Shunji, Morimoto, Takashi, Akiyama, Futoshi, Kurosumi, Masafumi, Tsuda, Hitoshi, Mikami, Yoshiki, Tanaka, Sunao, Morita, Satoshi, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010720/
https://www.ncbi.nlm.nih.gov/pubmed/29733541
http://dx.doi.org/10.1002/cam4.1516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010720/
https://www.ncbi.nlm.nih.gov/pubmed/29733541
http://dx.doi.org/10.1002/cam4.1516

Ejemplares similares